



## GLAXOSMITHKLINE RESPONDS TO LETTER FROM SENATOR GRASSLEY

PHILADELPHIA, PENNSYLVANIA – January 30, 2008 - On May 3, 2007, a peer reviewer contacted GlaxoSmithKline (GSK) about an article related to *Avandia*® (rosiglitazone maleate) that he had been asked to review by the *New England Journal of Medicine*. The reviewer told GlaxoSmithKline he had concerns and questions regarding the methodology of the analysis, and sent the article to GlaxoSmithKline for advice from experienced statisticians. GlaxoSmithKline did not provide comments or any other input on the manuscript to the reviewer. We believe GlaxoSmithKline acted appropriately and responsibly in responding to the situation.

### Inquiries

#### US Media inquiries:

Nancy Pekarek (215) 751 7709  
Mary Anne Rhyne (919) 483 2839

#### UK Media inquiries:

Phil Thomson (020) 8047 5502  
Alice Hunt (020) 8047 5502  
Joss Mathieson (020) 8047 5502  
Claire Brough (020) 8047 5502

#### US Analyst/ Investor inquiries:

Frank Murdolo (215) 751 7002  
Tom Curry (215) 751 5419

#### European Analyst/Investor inquiries:

David Mawdsley (020) 8047 5564  
Sally Ferguson (020) 8047 5543